托法替布治疗活动性银屑病关节炎长达48个月的安全性和疗效:OPAL Balance长期扩展研究最终分析
OPAL Balance是一项开放标签长期扩展研究,纳入686例活动性银屑病关节炎患者,评估托法替布5mg或10mg每日两次的安全性和疗效。结果显示长达48个月的安全性结果与既往3期研究一致,疗效维持至36个月。
要点
- 托法替布治疗银屑病关节炎的安全性特征与既往3期研究一致,长达48个月。
- 疗效在36个月时仍维持。
- 特别关注不良事件发生率较低,包括带状疱疹、严重感染、恶性肿瘤和主要心血管不良事件。
核心结论
- 托法替布在银屑病关节炎患者中长达48个月的安全性结果与既往3期研究一致,疗效维持至36个月。
研究设计与样本
- 开放标签长期扩展研究,在16个国家124个中心进行,纳入完成OPAL Broaden或OPAL Beyond研究的活动性银屑病关节炎患者,共686例接受托法替布5mg或10mg每日两次治疗。
- 包含一个随机双盲甲氨蝶呤撤药子研究(179例),安全性数据报告至第48个月,疗效数据报告至第36个月(子研究数据除外)。
主要发现
- 截至第48个月,686例中574例(84%)报告全因不良事件,115例(17%)报告严重不良事件,78例(11%)因不良事件停药。
- 未发生深静脉血栓。实验室参数变化与治疗预期一致。疗效维持至第36个月。
关键数值与推荐
- 主要终点为不良事件的发生率和严重程度、实验室异常的发生率以及实验室参数相对于基线的变化。
临床怎么用
- 该研究支持托法替布在银屑病关节炎患者中长达48个月的安全性以及长达36个月的疗效,与既往3期研究一致。
局限性
- 开放标签扩展研究设计可能引入偏倚;子研究数据仅报告安全性,疗效数据未包括子研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis. Here we report the final analysis of Oral Psoriatic Arthritis Trial (OPAL) Balance, a 36-month long-term extension study, with a 12-month methotrexate withdrawal substudy, that assessed tofacitinib safety, tolerability, and efficacy in patients with active psoriatic arthritis. METHODS: For this open-label, long-term extension study, which was run at 124 centres in 16 countries, eligible patients had participated in the OPAL Broaden or OPAL Beyond phase 3 studies. Patients could enter OPAL Balance up to 3 months after completing one of the qualifying studies or discontinuing for reasons other than an adverse event related to study drug. In OPAL Balance, patients received open-label tofacitinib 5 mg twice daily, with increases to 10 mg twice daily for inadequate symptom control allowed from month 1, and reductions to 5 mg twice daily allowed thereafter for safety. Specific conventional synthetic disease-modifying antirheumatic drugs could be continued concomitantly. The primary endpoints were incidence and severity of adverse events, the incidence of laboratory abnormalities, and changes from baseline in laboratory parameters. Participants who were eligible could enter the randomised, double-blind, methotrexate withdrawal substudy (open-label tofacitinib 5 mg twice daily plus either masked placebo or masked methotrexate); safety data from which are included here (up to month 48). Efficacy was reported up to month 36 (substudy data excluded). The risk period for safety outcomes was the time from treatment exposure to the last dose plus 28 days or date of last observation. OPAL Balance is registered with ClinicalTrials.gov (NCT01976364) and is now complete. FINDINGS: Between Feb 17, 2014, and March 28, 2016, 686 patients were enrolled and given tofacitinib 5 mg or 10 mg twice daily (179 patients were treated in the substudy and 453 [66%] of 686 completed the long-term extension study or substudy; mean treatment duration 794·6 days [SD 329·2] in long-term extension study, 879·0 days [396·6] in long-term extension study plus substudy). The mean age of participants in the all tofacitinib group was 48·8 years (SD 11·8) and 370 (54%) of 686 participants were female. Up to month 48, 574 (84%) of 686 participants reported all-cause adverse events, 115 (17%) reported serious adverse events, and 78 (11%) discontinued due to an adverse event. Six patients died, one within the risk period (incidence of 0·1 patients with events [95% CI 0·0-0·3] per 100 person-years). The incidences of adverse events of special interest, reported as number of patients with events per 100 person-years, included: 1·7 (1·2-2·5) for herpes zoster (non-serious and serious); 1·0 (0·6-1·6) for serious infections; 0·4 (0·1-0·8) for opportunistic infections; 0·7 (0·4-1·2) for malignancies (excluding non-melanoma skin cancer [NMSC]); 0·9 (0·5-1·5) for NMSC; 0·2 (0·1-0·6) for major adverse cardiovascular events; 0·1 (0·0-0·3) for pulmonary embolism; and 0·4 (0·1-0·8) for arterial thromboembolism. No deep vein thromboses occurred. Laboratory parameter changes were as expected with treatment. Efficacy was sustained up to month 36. INTERPRETATION: This analysis supports the long-term safety (up to 48 months) and efficacy (up to 36 months) of tofacitinib in patients with psoriatic arthritis, which were consistent with previous phase 3 studies. FUNDING: Pfizer.
引用
- Nash P, Coates LC, Fleishaker D, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatol. 2021. PMID: 38279411. doi:10.1016/S2665-9913(21)00010-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。